All In Biotech

Drug Trial Radar · NCT06389487

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

A Phase 3b, Open-label Study to Evaluate the Non-inferiority of the Immune Response and to Evaluate the Safety of the RSVPreF3 OA Investigational Vaccine in Adults 18-49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults >=60 Years of Age

Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,459

Actual

Start

Apr 29, 2024

Primary completion

Jul 29, 2024

Study completion Mar 18, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Apr 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV disease, compared to older adults (OA) 60 YOA and above.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • RSVPreF3 OA investigational vaccineBiological

    1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)Time frame: At Day 31
  2. Part A: Percentage of Participants With Seroresponse Rate (SRR) in RSV-A Neutralizing TitersTime frame: Day 31 compared with baseline (Day 1)
  3. Part A: RSV-B Neutralizing Titers Expressed as Group GMTsTime frame: At Day 31
  4. Part A: Percentage of Participants With SRR in RSV-B Neutralizing TitersTime frame: Day 31 compared with baseline (Day 1)

Locations

52 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Glendale, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    North Hollywood, California

  • GSK Investigational Site

    Oakland, California

  • GSK Investigational Site

    Walnut Creek, California

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    North Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Silver Spring, Maryland

  • GSK Investigational Site

    Rochester, New York

  • GSK Investigational Site

    Oklahoma City, Oklahoma

  • GSK Investigational Site

    Knoxville, Tennessee

  • GSK Investigational Site

    DeSoto, Texas

  • GSK Investigational Site

    Charlottesville, Virginia

  • GSK Investigational Site

    Wenatchee, Washington

  • GSK Investigational Site

    Coffs Harbour, New South Wales, Australia

  • GSK Investigational Site

    Sydney, New South Wales, Australia

  • GSK Investigational Site

    Sydney, New South Wales, Australia

  • GSK Investigational Site

    Fortitude Valley, Queensland, Australia

  • GSK Investigational Site

    Tarragindi, Queensland, Australia

  • GSK Investigational Site

    Melbourne, Victoria, Australia

  • GSK Investigational Site

    St Albans, Victoria, Australia

  • GSK Investigational Site

    New Westminster, British Columbia, Canada

  • GSK Investigational Site

    Victoria, British Columbia, Canada

  • GSK Investigational Site

    Truro, Nova Scotia, Canada

  • GSK Investigational Site

    Greater Sudbury, Ontario, Canada

  • GSK Investigational Site

    Guelph, Ontario, Canada

  • GSK Investigational Site

    London-Ontario, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Saint-Charles-Borromée, Quebec, Canada

  • GSK Investigational Site

    Sherbrooke, Quebec, Canada

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Essen, Germany

  • GSK Investigational Site

    Mainz, Germany

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.